A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration

Registry ID

EUCTR2009-015106-19

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxoSmithKline Research and Development

Start date

2009-12-07

Completion date

2012-10-05

Last update

2026-08-16

Conditions

• Age-Related Macular Degeneration
• Neovascular age-related macular degeneration.

Summary

To evaluate if pazopanib eye drops can maintain or possibly improve vision, while reducing the continued need for intravitreal injections.

Locations

• , , Italy
• , , Sweden
• , , Belgium
• , , Germany
• , , Denmark

Related clinical trials

• Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
• AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
• A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
• A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
• Effects of Goji vs. Fiber on Macular Degeneration
• Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

View on source registry